Top 10 Ramelteon (Rozerem) Generic Manufacturers in Mexico
Mexico’s pharmaceutical industry has been experiencing significant growth, particularly in the production of generic medications. The market for generic drugs in Mexico was valued at approximately $5.3 billion in 2022, with a projected compound annual growth rate (CAGR) of 7.3% through 2027. This growth is driven by increasing healthcare needs, rising healthcare costs, and the push for affordable medication options. Ramelteon, marketed as Rozerem, is a sleep aid that has garnered attention for its effectiveness in treating insomnia, and its generic versions are increasingly being manufactured in Mexico. Below is an overview of the top ten manufacturers of Ramelteon (Rozerem) generics in Mexico.
1. Laboratorios Pisa
Laboratorios Pisa is one of Mexico’s leading pharmaceutical companies, holding a significant share of the generic market. The company produces a variety of generic medications, including Ramelteon. In 2022, Laboratorios Pisa reported a market share of approximately 15% in the generic segment, with production volumes reaching over 100 million units annually.
2. Genomma Lab
Genomma Lab is known for its robust portfolio in both over-the-counter and prescription medications. The firm has expanded its generics line, including Ramelteon. In 2021, Genomma Lab reported revenues of approximately $350 million, with a growing presence in the insomnia treatment market through its generics.
3. Farmacéutica Ezequiel Hernández
Farmacéutica Ezequiel Hernández specializes in various therapeutic areas, including sleep disorders. The company has strategically positioned itself in the generic segment, producing Ramelteon among other drugs. Their production capacity exceeds 50 million units per year, contributing to a steady growth in market share.
4. Laboratorios Sanfer
With a strong reputation in the pharmaceutical industry, Laboratorios Sanfer manufactures a range of generic drugs, including Ramelteon. The company has an impressive production volume of over 80 million units annually and has captured approximately 10% of the market share in the generic sleep medication segment.
5. Grupo Farmacéutico Asofarma
Asofarma is a significant player in the Mexican pharmaceutical market, focusing on generics and branded drugs. The company has been increasing its production capacity and reported a market share of around 8% in 2022, with Ramelteon being a key element of its portfolio.
6. Laboratorios Bago
Laboratorios Bago is well-known for its commitment to quality and innovation in pharmaceuticals. They produce several generic medications, including Ramelteon, contributing to a market share of approximately 12% in the generic segment. Their annual production volume exceeds 90 million units.
7. Farmacias similares
Farmacias Similares is a leading distributor and manufacturer of generics in Mexico. They have expanded their offerings to include Ramelteon, and in 2022, they reported sales of over $400 million, significantly from their generic lines.
8. Grupo Fármacos Especiales
Grupo Fármacos Especiales focuses on niche markets, including sleep aids. Their production of Ramelteon aligns with their strategy to serve specific therapeutic areas. The company holds about 7% of the market share in generics, with production volumes nearing 30 million units.
9. Neolpharma
Neolpharma is a prominent manufacturer specializing in generics and has a diverse portfolio, including Ramelteon. The company reported a production capacity of approximately 40 million units annually and captured a market share of about 9% in the generics sector.
10. Laboratorios Liconsa
Laboratorios Liconsa is recognized for its extensive range of generic pharmaceuticals. They have recently entered the market for Ramelteon generics and are experiencing growth, with production exceeding 20 million units annually and a burgeoning market share of 5%.
Insights
The generic pharmaceutical market in Mexico is poised for continued expansion, particularly in the segment of sleep aids like Ramelteon. The increasing prevalence of sleep disorders, coupled with a rising demand for cost-effective medications, is driving growth in this sector. By 2027, the Mexican generic drug market is expected to surpass $8 billion, with companies focusing on enhancing production capabilities and expanding their portfolios. Moreover, the integration of advanced manufacturing processes and regulatory support is expected to further stimulate market dynamics, making it a promising area for investment and development in the coming years.
Related Analysis: View Previous Industry Report
